Total Funding
$416M
Employee Range
11-50
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses.
Upstream Bio data powered by:
Share
Upstream Bio data powered by:
Upstream BioOverall Ranking
National Rank
Share
Loading...
In United States
Top null%out of startups
Regional Rank
Share
Loading...
In North America
Top null%out of startups
Upstream BioIndustry Rankings in
Healthtech
City Rank
Share
10th
In Waltham
Top 24%out of 42 startups
National Rank
Share
602nd
In United States
Top 7%out of 8858 startups
Regional Rank
Share
624th
In North America
Top 7%out of 9654 startups
Upstream BioSubindustry Rankings in
BiotechnologyCity Rank
Share
5th
In Waltham
Top 16%out of 33 startups
National Rank
Share
179th
In United States
Top 6%out of 3469 startups
Regional Rank
Share
184th
In North America
Top 5%out of 3717 startups
rankings by:
Upstream BioSB Rank Evolution
Not enough data points to display the chart.
Upstream BiostartupComparison
National Ranking (undefined)
Loading...
...
Regional Ranking (undefined)
Loading...
...
Global Ranking (WorldWide)
Loading...
...
Industry Ranking (undefined)
Loading...
...
SubIndustry Ranking (undefined)
Loading...
...
See all ranked entities with a premium subscription
Get Pro